封面
市場調查報告書
商品編碼
1435119

骨質疏鬆症和骨折治療藥物市場:按藥物、給藥途徑和分佈分類 - 2024-2030 年全球預測

Anti-Osteoporosis Therapy & Fracture Healing Market by Drug (Alendronate, Biophosphonates, Ibandronate), Route Of Administration (Injectable, Oral), Distribution - Global Forecast 2024-2030

出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

骨質疏鬆和骨折藥物的市場規模預計2023年為138億美元,2024年達到149.7億美元,預計2030年將達到244.8億美元,複合年成長率為8.53%。

骨質疏鬆症和骨折治療藥物的全球市場

主要市場統計
基準年[2023] 138億美元
預測年份 [2024] 149.7億美元
預測年份 [2030] 244.8億美元
複合年成長率(%) 8.53%
抗骨質疏鬆治療及骨折癒合市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估骨質疏鬆症和骨折治療市場極為重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。

市場佔有率分析

市場佔有率分析是一種綜合工具,可以對骨質疏鬆症和骨折治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解:

1-市場滲透率:提供有關主要企業所服務的市場的全面資訊。

2-市場開拓:我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題:

1-骨質疏鬆症和骨折治療藥物市場的市場規模和預測是多少?

2-骨質疏鬆藥物/骨折藥物市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些?

3-骨質疏鬆症和骨折治療藥物市場的技術趨勢和法律規範是什麼?

4-骨質疏鬆和骨折治療藥物市場主要供應商的市場佔有率是多少?

5-進入骨質疏鬆/骨折治療藥物市場的合適型態和策略性手段是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的老年人口正在增加
      • 由於快速的都市化和生活方式的改變,

骨病的發生

      • 女性停經後骨質疏鬆症發生率增加
    • 抑制因素
      • 抗骨質疏鬆藥物和骨折癒合治療費用高昂
    • 機會
      • 擴大新藥引進的研究與開發
      • 持續認知骨質疏鬆症及其對健康的影響
    • 任務
      • 與抗骨質疏鬆藥物和骨折癒合相關的併發症和副作用
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章 骨質疏鬆症治療/骨折治療藥品市場依藥品分類

  • 阿崙膦酸鈉
  • 生物磷酸鹽
  • Ibandronate sodium
  • 利塞膦酸鹽
  • 選擇性雌激素受體調節
    • Raloxifene
    • 鍶雷尼特
  • Zoledronic acid

第7章骨質疏鬆症和骨折治療藥物市場:依給藥途徑

  • 可注射的
  • 口服

第8章骨質疏鬆症治療藥物/骨折治療藥物市場分佈

  • 藥局
  • 電子商務市場
  • 醫院
  • 私人診所
  • 零售藥房

第9章 北美和南美骨質疏鬆症和骨折治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區骨質疏鬆和骨折藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的骨質疏鬆和骨折藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析:主要企業
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • Amgen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Healthy Life Pharma Pvt. Ltd.
    • Johnson & Johnson Services, Inc.
    • Manus Aktteva Biopharma LLP
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Salvavidas Pharmaceutical Private Limited
    • Sanofi SA
    • Taj Pharmaceuticals
    • Taj Pharmaceuticals Limited
    • Teva Pharmaceuticals Industries Ltd
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-CA17E905EAD9

[186 Pages Report] The Anti-Osteoporosis Therapy & Fracture Healing Market size was estimated at USD 13.80 billion in 2023 and expected to reach USD 14.97 billion in 2024, at a CAGR 8.53% to reach USD 24.48 billion by 2030.

Global Anti-Osteoporosis Therapy & Fracture Healing Market

KEY MARKET STATISTICS
Base Year [2023] USD 13.80 billion
Estimated Year [2024] USD 14.97 billion
Forecast Year [2030] USD 24.48 billion
CAGR (%) 8.53%
Anti-Osteoporosis Therapy & Fracture Healing Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Osteoporosis Therapy & Fracture Healing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Osteoporosis Therapy & Fracture Healing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Osteoporosis Therapy & Fracture Healing Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Healthy Life Pharma Pvt. Ltd., Johnson & Johnson Services, Inc., Manus Aktteva Biopharma LLP, Merck & Co., Inc., Novartis AG, Pfizer Inc., Salvavidas Pharmaceutical Private Limited, Sanofi S.A., Taj Pharmaceuticals, Taj Pharmaceuticals Limited, and Teva Pharmaceuticals Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Anti-Osteoporosis Therapy & Fracture Healing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Alendronate
    • Biophosphonates
    • Ibandronate
    • Risedronate
    • Selective Oestrogen Receptor Modulators
      • Raloxifene
      • Strontium Ranelete
    • Zoledronic Acid
  • Route Of Administration
    • Injectable
    • Oral
  • Distribution
    • Drug Stores
    • E-Commerce Market
    • Hospitals
    • Private Clinics
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anti-Osteoporosis Therapy & Fracture Healing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Osteoporosis Therapy & Fracture Healing Market?

3. What are the technology trends and regulatory frameworks in the Anti-Osteoporosis Therapy & Fracture Healing Market?

4. What is the market share of the leading vendors in the Anti-Osteoporosis Therapy & Fracture Healing Market?

5. Which modes and strategic moves are suitable for entering the Anti-Osteoporosis Therapy & Fracture Healing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anti-Osteoporosis Therapy & Fracture Healing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population worldwide
      • 5.1.1.2. Rapid urbanization coupled with changing lifestyle is increasing the

occurrence of bone diseases

      • 5.1.1.3. Growing incidences of postmenopausal osteoporosis in women
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the anti-osteoporosis medications & fracture healing treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research and development in introduction of new drugs
      • 5.1.3.2. Ongoing awareness of osteoporosis and its impact on health
    • 5.1.4. Challenges
      • 5.1.4.1. Complication and side effects related to with anti-osteoporosis medications & fracture healing
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anti-Osteoporosis Therapy & Fracture Healing Market, by Drug

  • 6.1. Introduction
  • 6.2. Alendronate
  • 6.3. Biophosphonates
  • 6.4. Ibandronate
  • 6.5. Risedronate
  • 6.6. Selective Oestrogen Receptor Modulators
    • 6.7.1. Raloxifene
    • 6.7.2. Strontium Ranelete
  • 6.7. Zoledronic Acid

7. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Distribution

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. E-Commerce Market
  • 8.4. Hospitals
  • 8.5. Private Clinics
  • 8.6. Retail Pharmacies

9. Americas Anti-Osteoporosis Therapy & Fracture Healing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anti-Osteoporosis Therapy & Fracture Healing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anti-Osteoporosis Therapy & Fracture Healing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Amgen Inc.
    • 13.1.2. Eli Lilly and Company
    • 13.1.3. F. Hoffmann-La Roche Ltd.
    • 13.1.4. GlaxoSmithKline plc
    • 13.1.5. Healthy Life Pharma Pvt. Ltd.
    • 13.1.6. Johnson & Johnson Services, Inc.
    • 13.1.7. Manus Aktteva Biopharma LLP
    • 13.1.8. Merck & Co., Inc.
    • 13.1.9. Novartis AG
    • 13.1.10. Pfizer Inc.
    • 13.1.11. Salvavidas Pharmaceutical Private Limited
    • 13.1.12. Sanofi S.A.
    • 13.1.13. Taj Pharmaceuticals
    • 13.1.14. Taj Pharmaceuticals Limited
    • 13.1.15. Teva Pharmaceuticals Industries Ltd
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET DYNAMICS
  • FIGURE 7. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 8. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 12. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BIOPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 12. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STRONTIUM RANELETE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY E-COMMERCE MARKET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 192. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 193. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET LICENSE & PRICING